OA11421A - An over-expressing homologous antigen vaccine and a method of making the same. - Google Patents

An over-expressing homologous antigen vaccine and a method of making the same. Download PDF

Info

Publication number
OA11421A
OA11421A OA1200000163A OA1200000163A OA11421A OA 11421 A OA11421 A OA 11421A OA 1200000163 A OA1200000163 A OA 1200000163A OA 1200000163 A OA1200000163 A OA 1200000163A OA 11421 A OA11421 A OA 11421A
Authority
OA
OAPI
Prior art keywords
gene
vaccine
attenuated
pathogen
organism
Prior art date
Application number
OA1200000163A
Other languages
English (en)
Inventor
Stephen M Boyle
Lynette Corbeil
Silvio Cravero
Gerhardt G Schurig
Nammalwar Srimaganathan
Ramesh Vemulapalli
Original Assignee
Virginia Tech Intell Prop
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CNB971825173A priority Critical patent/CN1321693C/zh
Priority to PT97953216T priority patent/PT1035863E/pt
Priority to AU57013/98A priority patent/AU759776C/en
Priority to US09/091,521 priority patent/US6149920A/en
Priority to EP97953216A priority patent/EP1035863B1/fr
Priority to CA002317806A priority patent/CA2317806A1/fr
Priority to NZ504993A priority patent/NZ504993A/xx
Priority to PCT/US1997/023032 priority patent/WO1999029340A1/fr
Priority to ES97953216T priority patent/ES2259449T3/es
Priority to BRPI9714904-7A priority patent/BR9714904B1/pt
Priority to AT97953216T priority patent/ATE320264T1/de
Application filed by Virginia Tech Intell Prop filed Critical Virginia Tech Intell Prop
Priority to OA1200000163A priority patent/OA11421A/en
Priority to US09/692,623 priority patent/US6811787B1/en
Publication of OA11421A publication Critical patent/OA11421A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/23—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Brucella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
OA1200000163A 1997-12-05 2000-06-05 An over-expressing homologous antigen vaccine and a method of making the same. OA11421A (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
NZ504993A NZ504993A (en) 1997-12-05 1997-12-05 A vaccine comprising a pathogen that over-expresses a homologous antigen
AU57013/98A AU759776C (en) 1997-12-05 1997-12-05 An over-expressing homologous antigen vaccine and a method of making the same
US09/091,521 US6149920A (en) 1997-12-05 1997-12-05 Over-expressing homologous antigen vaccine and a method of making the same
EP97953216A EP1035863B1 (fr) 1997-12-05 1997-12-05 Vaccin contenant un alloantigene surexprime et son procede de preparation
CA002317806A CA2317806A1 (fr) 1997-12-05 1997-12-05 Vaccin contenant un alloantigene surexprime et son procede de preparation
CNB971825173A CN1321693C (zh) 1997-12-05 1997-12-05 一种过量表达的同源抗原疫苗及其制备方法
AT97953216T ATE320264T1 (de) 1997-12-05 1997-12-05 Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung
PCT/US1997/023032 WO1999029340A1 (fr) 1997-12-05 1997-12-05 Vaccin contenant un alloantigene surexprime et son procede de preparation
BRPI9714904-7A BR9714904B1 (pt) 1997-12-05 1997-12-05 vacina antìgena homóloga e microorganismo transgênico para a mesma.
PT97953216T PT1035863E (pt) 1997-12-05 1997-12-05 Vacina de antigenio homologo sobre-expressante e um metodo para produzir a mesma
ES97953216T ES2259449T3 (es) 1997-12-05 1997-12-05 Vacuna de antigeno homologo sobreexpresado y procedimiento para la preparacion de la misma.
OA1200000163A OA11421A (en) 1997-12-05 2000-06-05 An over-expressing homologous antigen vaccine and a method of making the same.
US09/692,623 US6811787B1 (en) 1997-12-05 2000-10-20 Over-expressing homologous antigen vaccine and a method of making the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNB971825173A CN1321693C (zh) 1997-12-05 1997-12-05 一种过量表达的同源抗原疫苗及其制备方法
PCT/US1997/023032 WO1999029340A1 (fr) 1997-12-05 1997-12-05 Vaccin contenant un alloantigene surexprime et son procede de preparation
OA1200000163A OA11421A (en) 1997-12-05 2000-06-05 An over-expressing homologous antigen vaccine and a method of making the same.
US09/692,623 US6811787B1 (en) 1997-12-05 2000-10-20 Over-expressing homologous antigen vaccine and a method of making the same

Publications (1)

Publication Number Publication Date
OA11421A true OA11421A (en) 2004-04-21

Family

ID=39591168

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000163A OA11421A (en) 1997-12-05 2000-06-05 An over-expressing homologous antigen vaccine and a method of making the same.

Country Status (12)

Country Link
US (2) US6149920A (fr)
EP (1) EP1035863B1 (fr)
CN (1) CN1321693C (fr)
AT (1) ATE320264T1 (fr)
AU (1) AU759776C (fr)
BR (1) BR9714904B1 (fr)
CA (1) CA2317806A1 (fr)
ES (1) ES2259449T3 (fr)
NZ (1) NZ504993A (fr)
OA (1) OA11421A (fr)
PT (1) PT1035863E (fr)
WO (1) WO1999029340A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE320264T1 (de) 1997-12-05 2006-04-15 Virginia Tech Intell Prop Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung
WO2002080964A1 (fr) * 2001-04-06 2002-10-17 Institut Pasteur Vaccin conjugue d'un fragment de polysaccharide de lipopolysaccharide du vibrio cholerae 0139 lie a l'anatoxine tetanique
US7416878B2 (en) * 2002-12-12 2008-08-26 The United States Of America As Represented By The Secretary Of The Army Immunogenic compositions including rough phenotype Brucella host strains and complementation DNA fragments
US7364745B2 (en) * 2004-02-06 2008-04-29 Virginia Tech Intellectual Properties, Inc. Development of a live, attenuated, recombinant vaccine for Brucellosis
WO2005084706A1 (fr) * 2004-03-03 2005-09-15 Walter Reed Army Institute Of Research Souches mutantes de brucella melitensis et compositions immunogenes
US20060115494A1 (en) * 2004-12-01 2006-06-01 Ronggai Sun Recombinant BCG strains with attenuated immunosuppressive properties

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US5468485A (en) * 1987-06-04 1995-11-21 Washington University Avirulent microbes and uses therefor
US6043057A (en) 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
CA2156191A1 (fr) 1993-02-22 1994-09-01 Stephen B. Calderwood Antigenes heterologues dans des souches cellulaires vivantes de vaccin
ATE335083T1 (de) * 1993-02-26 2006-08-15 Novozymes As Methode und system zur erhöhten produktion von kommerziell wichtigen exoproteinen in gram- positiven bakterien
ES2171454T3 (es) 1993-06-04 2002-09-16 Whitehead Biomedical Inst Proteinas de estres y sus usos.
WO1998023763A1 (fr) 1996-11-29 1998-06-04 The General Hospital Corporation Antigenes heterologues exprimes dans des souches de cellules vivantes v. cholerae
AU6969798A (en) * 1997-04-15 1998-11-11 Baylor College Of Medicine (pasteurella haemolytica) vaccine
ATE320264T1 (de) * 1997-12-05 2006-04-15 Virginia Tech Intell Prop Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung

Also Published As

Publication number Publication date
EP1035863A4 (fr) 2003-04-16
AU759776B2 (en) 2003-05-01
EP1035863A1 (fr) 2000-09-20
BR9714904A (pt) 2001-11-27
AU5701398A (en) 1999-06-28
AU759776C (en) 2004-05-20
US6149920A (en) 2000-11-21
US6811787B1 (en) 2004-11-02
CN1290173A (zh) 2001-04-04
CA2317806A1 (fr) 1999-06-17
BR9714904B1 (pt) 2010-07-13
ATE320264T1 (de) 2006-04-15
WO1999029340A1 (fr) 1999-06-17
ES2259449T3 (es) 2006-10-01
CN1321693C (zh) 2007-06-20
NZ504993A (en) 2002-11-26
PT1035863E (pt) 2006-07-31
EP1035863B1 (fr) 2006-03-15

Similar Documents

Publication Publication Date Title
US20080069843A1 (en) Salmonella vaccine
CA2292900A1 (fr) Vaccin vivant attenue
US20080254062A1 (en) Use of an avirulent bordetella mutant as a live vaccine vector
CA2429120C (fr) Vaccin contre la salmonelle
Shimoji et al. Construction and vaccine potential of acapsular mutants of Erysipelothrix rhusiopathiae: use of excision of Tn 916 to inactivate a target gene
WO2008075075A1 (fr) Souche de francisella pour un vaccin vivant
OA11421A (en) An over-expressing homologous antigen vaccine and a method of making the same.
JPH11514878A (ja) アクチノバシラス・プリゥロニュウモニエｒｔｘ毒素ａｐｘに対する免疫
US20030044431A1 (en) Over-expressing homologous antigen vaccine and a method of making the same
Pretorius et al. Protection against heartwater by DNA immunisation with four Ehrlichia ruminantium open reading frames
US5939075A (en) Mutants of Brucella melitensis
PL188925B1 (pl) Szczepionka przeciwko brucelozie, osłabiona lub awirulentna odmiana szczepu RB51 B. abortus, zastosowanie szczepionki, sposób wytwarzania szczepionki
US7332324B2 (en) Attenuated vaccine useful for immunizations against Coccidioides spp. infections
MXPA00005513A (en) An over-expressing homologous antigen vaccine and a method of making the same
KR101797276B1 (ko) 다중 돌연변이된 살모넬라 티피뮤리움 균주 및 이를 포함하는 식중독 예방 백신 조성물
World Health Organization The Development of new
EP0554335A1 (fr) Corynebacteries et autres organismes apparentes utilises comme vecteurs de vaccin